PepPool: BKV (CD4 and CD8), human

PepPool: BKV (CD4 and CD8), human

3675-1

Publications: 0
Documents
Questions?
Validated for our assays.

Content

Peptide pool with 65 peptides, 25 ug of each peptide. Supplied in one vial (lyophilized).

In stock

Delivery 4-9 business days

Shipping $0

Product specifications

Intended use

This peptide pool is intended for studying immune responses against BK polyomvirus (BKV) using immunoassays such as ELISpot and FluoroSpot. It induces cytokine secretion from antigen-specific human T cells. For research use only. Not for use in diagnostic procedures.

Serum/Plasma samples

Description
This peptide pool induces secretion of e.g., IFN-γ from human CD4 and CD8 T cells. It contains 65 synthetic peptides derived from the BKV large T protein, small T protein, and VP1 protein. 50 of the peptides are MHC class I-restricted and 15 are MHC class II-restricted. The peptide pool is designed to stimulate T cells with a broad array of HLA class I supertypes. Sequence similarity to corresponding JC virus (JCV) peptides ranges from 60% to 100%, with a median sequence similarity of 80%.

Recommendation

Product details

ProductPepPool: BKV (CD4 and CD8), human
ApplicationT cell stimulation, ELISpot, FluoroSpot
ReactivityHuman
ConcentrationOne vial with 25 µg of each peptide
Supplied in

Lyophilized

Contents

Peptide pool with 65 peptides, 25 ug of each peptide. Supplied in one vial (lyophilized).

Shipping and Storage

Shipping

Shipped at ambient temperature.

Storage

Store at -20 °C or below upon receipt. 

Human PBMC (250,000 cells/well) were incubated for 20 h in the absence or presence of PepPool: BKV (CD4 + CD8), human, and the number of cells secreting IFN-γ was analyzed by ELISpot. Analysis was done with Mabtech IRIS. 

Datasheet/Protocol
SDS

Highlighted research, Published October 28, 2024

Immunoassays for infectious disease research
Explore the role of immunoassays like ELISpot and FluoroSpot in infectious disease research. Discover how Mabtech's immunoassays enable researchers to study immune responses at the cellular level for diseases like TB, SARS-CoV-2, Malaria, HIV, and more.

Highlighted research, Published October 28, 2024

T cell therapy treats BKV in transplant patients
This study demonstrates the success of virus-specific T cell therapy in treating BK virus (BKV) infections in immunocompromised transplant patients. ELISpot confirmed the expansion of BKV-specific T cells, with high response rates and no adverse effects, highlighting the therapy's potential.

Featured product, Published March 17, 2023

BKV PepPool available
We added a new peptide pool to our webshop – PepPool: BKV (CD4 and CD8), human.
Loading publications...